PET/CT Imaging of uPAR-expression in Patients With Neuroendocrine Tumors Using 68Ga-NOTA-AE105
Status:
Completed
Trial end date:
2021-07-08
Target enrollment:
Participant gender:
Summary
The aim of this non-randomised, prospective study is to investigate the applicability and
prognostic value of uPAR PET/CT with the radioligand 68Ga-NOTA-AE105 in patients with
neuroendocrine tumors (NETs).